[Gastroesophageal reflux. Results of a multicenter study of 170 patients on the therapeutic value of the Gaviscon drinkable suspension].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000464:Alginates / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000627:therapeutic use*; D001639:Bicarbonates / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D012824:Silicic Acid / Q000627:therapeutic use*; D012822:Silicon Dioxide / Q000627:therapeutic use*; D017693:Sodium Bicarbonate; D012996:Solutions
D000464:Alginates; D001639:Bicarbonates; D004338:Drug Combinations; D012996:Solutions; D012824:Silicic Acid; D000536:Aluminum Hydroxide; C007829:alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; D012822:Silicon Dioxide; D017693:Sodium Bicarbonate
Le reflux gastro-oesophagien. Intérêt thérapeutique du Gaviscon suspension buvable résultat d'une étude multicentrique portant sur 170 patients.